Aptamer News and Research

RSS

Novel DNA aptamers of melanopsin developed to regulate circadian rhythm

DNA aptamers of melanopsin that regulate the clock hands of biological rhythms were developed by the Toyohashi University of Technology and the National Institute of Advanced Industrial Science and Technology (AIST) group.

12 Jul 2024

Update on progress in Unilever partnership

Aptamer Group, the developer of novel Optimer® binders to enable innovation in the life sciences industry, is providing an update on the partnership with Unilever to deliver Optimer binders for cosmetic applications.

From Aptamer Group 9 Jul 2024

Agreement to explore Optimer vehicles for targeted delivery of siRNA

New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA.

From Aptamer Group 9 Jul 2024

Innovative aptamer cream shows promise in treating allergic contact dermatitis in mice

Researchers at the University of Bonn have isolated a DNA molecule that is suitable for combating allergic contact dermatitis in mice.

4 Jul 2024

Partnership with Microsaic Systems for Optimer-enabled water monitoring

New binders will be developed to multiple waterborne pathogens. Optimer will support continuous water monitoring for rapid detection.

From Aptamer Group 14 Jun 2024

Aptamer and Timser partner to deliver world’s first blood test for cervical cancer

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women’s health, with a deal value of up to £465,000.

From Aptamer Group 22 May 2024

Top pharmaceutical company evaluates Optimer for precision liver medicine

Optimer delivery vehicle has been shipped to a pharma partner for external evaluation.

From Aptamer Group 22 Apr 2024

Patent submission for Optimer® binders in cosmetic products

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has filed a patent application to protect the recently developed Optimer binder sequences for novel applications in fast moving consumer goods generated as part of its partnership with Unilever.

From Aptamer Group 10 Apr 2024

DNA aptamer-based sensors can accurately detect trace amounts of fentanyl, heroin, and cocaine

Researchers from North Carolina State University have developed a new generation of high-performance DNA aptamers and highly accurate drug sensors for cocaine and other opioids.

5 Mar 2024

Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development

Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, announces the second phase of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease, to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease

From Aptamer Group 22 Feb 2024

Wastewater clues could revolutionize Alzheimer's detection

Review explores the potential of wastewater-based epidemiology (WBE) for diagnosing Alzheimer's disease (AD) through biomarkers in biofluids, offering a non-invasive, cost-effective approach to early detection and large-scale monitoring.

18 Feb 2024

Study finds patients with long COVID exhibit complement dysregulation with signs of thromboinflammation

Researchers explore inflammatory signatures restricted to patients with active post-acute COVID-19 sequelae.

23 Jan 2024

Revolutionary RNA-based switch offers new control over gene expression in mammalian cells

Researchers developed an RNA-based switch, the pA regulator system, to control gene expression in mammalian cells by modulating synthetic polyA signal cleavage, offering a novel approach for gene therapy applications.

4 Jan 2024

Non-invasive monitoring of glucose and adenosine monophosphate biomarkers in saliva

Blood tests are a common, yet often painful, step in health care. But what if we could skip the needles altogether? Saliva and blood contain many of the same biomarkers, and collecting spit is as simple as drooling into a container.

29 Nov 2023

Non-invasive device detects Alzheimer's and Parkinson's biomarkers with high accuracy

An international team of researchers has developed a handheld, non-invasive device that can detect biomarkers for Alzheimer's and Parkinson's Diseases.

13 Nov 2023

DNA aptamers: A versatile tool for regenerative medicine and beyond

Generating specific cell lineages from induced pluripotent stem cells and embryonic stem cells is the holy grail of regenerative medicine.

10 Oct 2023

Researchers develop new, modular strategy for T-cell-based immunotherapy

Immunotherapies for cancer aim to induce the immune system to combat cancer cells more effectively.

25 Aug 2023

New DNA-based anticoagulant could treat heparin-induced thrombocytopenia

Various medical circumstances, including heart attacks and extreme cases of COVID-19, necessitate the use of anticoagulants, medicines that prevent blood clots

21 Aug 2023

Merck awards 2023 Future Insight Prize for research into air sensor to detect pandemic pathogens

Merck KGaA, Darmstadt, Germany, awarded its 2023 Future Insight Prize to Khalid Salaita, professor of chemistry at Emory University. The award comes with $540,000 to fund the next phase of research into an air sensor that can continuously monitor indoor spaces for pathogens that can cause pandemics.

17 Jul 2023

Phosphorothioate backbone modification enhances aptamer-drug conjugate for pancreatic cancer therapy

Pancreatic cancer is a complex and deadly solid tumor that poses significant challenges for both diagnosis and treatment.

10 Jul 2023